Can I Take Turmeric / Curcumin with AOD-9604?

The direct answer

There is no documented pharmacokinetic interaction between AOD-9604 and curcumin. AOD-9604 is degraded by circulating peptidases and cleared renally, not metabolized by the cytochrome P450 enzymes that curcumin can weakly inhibit, so curcumin is not expected to change AOD-9604 blood levels. The open question is pharmacodynamic: both agents touch inflammatory signaling, and curcumin independently has dose-dependent antiplatelet activity that becomes clinically relevant above roughly 500 mg to 1,000 mg per day of standardized extract or with high-bioavailability formulations, particularly in people also taking an anticoagulant. No published study has tested AOD-9604 and curcumin together, so this assessment is built from the separate pharmacology of each agent rather than direct combination data.

What AOD-9604 is, and why that shapes the interaction question

AOD-9604 was originally developed as an anti-obesity candidate and studied in Phase II/III trials before that development program ended. It is not an FDA-approved drug. Where it is available today, it is typically dispensed by 503A compounding pharmacies, which means there is no FDA-reviewed label, no official drug-interaction monograph, and no post-marketing adverse event database of the kind that exists for approved medicines. Anyone using it should understand that everything downstream of this fact, including interaction guidance, rests on mechanism-based reasoning and the pharmacology of the individual agents rather than on a regulator-reviewed interaction study.

Because it is a peptide, AOD-9604 is not metabolized like a small-molecule drug. It does not rely on hepatic CYP450 pathways for clearance the way many prescription medications do. That single fact is why classic "does this supplement induce or inhibit the enzyme that clears my drug" pharmacokinetic questions largely do not apply here. It also means the interaction analysis has to shift toward pharmacodynamics: what happens when two substances act on overlapping biological pathways at the same time, even if neither changes the other's blood concentration.

What curcumin does that is relevant here

Curcumin is the primary bioactive compound in turmeric and is available in very different strengths depending on formulation:

• Raw turmeric powder (roughly 2 to 5 percent curcumin by weight)
• Standardized 95 percent curcumin extract
• Bioavailability-enhanced formulations that add piperine (black pepper extract) or phospholipid complexes, both of which are well established in the pharmacology literature to substantially increase absorbed curcumin relative to standard extract

Curcumin has recognized anti-inflammatory activity through effects on NF-kB and related inflammatory signaling, and it has dose-dependent antiplatelet activity, meaning it can reduce platelet aggregation and modestly prolong bleeding time at higher intakes. It also weakly inhibits CYP3A4 and CYP1A2 in laboratory studies, though this has not been shown to produce clinically meaningful drug interactions with typical over-the-counter supplement doses in most reported human data. Case reports describing elevated INR in patients on warfarin who added high-dose turmeric do exist in the pharmacology literature, which is the basis for treating curcumin as an antiplatelet-adjacent supplement in anyone on a blood thinner.

None of these curcumin effects are unique to AOD-9604. They are the same considerations that apply when curcumin is combined with aspirin, NSAIDs, fish oil, vitamin E, or any other agent with antiplatelet or anti-inflammatory activity.

Where the two agents actually overlap

The table below is an evidence-status assessment, not a definitive risk score. It separates what current pharmacology supports from what is plausible extrapolation and what remains genuinely unknown for this specific combination.

The bleeding-risk question in practice

The realistic concern with this combination is not toxicity from combining the two agents. It is that AOD-9604 is typically self-administered by subcutaneous injection, and curcumin's antiplatelet activity, at high enough doses or with a high-bioavailability formulation, could plausibly contribute to more noticeable bruising at injection sites or slower bleeding after minor trauma. This is a monitoring consideration, not a contraindication, for someone taking a standard supplement-label dose of plain curcumin extract. It becomes a more serious conversation for anyone also on warfarin, apixaban, rivaroxaban, or another prescription anticoagulant, where the combined antiplatelet load deserves direct physician review, and for anyone using piperine- or phospholipid-enhanced curcumin at doses well above what the milligram number on the label might suggest, since those formulations increase absorbed curcumin substantially compared with standard extract.

Formulation matters more than the milligram number

A patient who says "I take 500 mg of turmeric" could mean very different things depending on the product. Standard 95 percent curcumin extract at 500 mg delivers modest systemic curcumin because oral bioavailability of unmodified curcumin is low. The same stated dose in a piperine-enhanced or phospholipid-complexed product delivers meaningfully more absorbed curcumin, and the pharmacodynamic effects, including the antiplatelet effect, scale with what is actually absorbed rather than with the label number alone. Anyone discussing this combination with a prescriber should specify the exact brand and formulation, not just the milligram dose.

Does timing matter?

For the injectable form of AOD-9604, there is no pharmacokinetic reason to separate the injection from oral curcumin intake, since one is absorbed subcutaneously and the other through the gut. If a patient is using an oral or sublingual AOD-9604 preparation, a modest separation (roughly two hours) is a reasonable precaution against any theoretical competition for gastrointestinal absorption, though this has not been specifically studied.

Who should get individualized medical review before combining these

• Anyone on a prescription anticoagulant or antiplatelet medication
• Anyone with a personal or family history of a bleeding disorder
• Anyone with gallstones or biliary obstruction, since curcumin stimulates bile secretion
• Anyone planning elective surgery, where both AOD-9604 and higher-dose curcumin are reasonable candidates for a pre-surgical pause given their overlapping antiplatelet-adjacent profile, following the same general logic applied to fish oil or vitamin E before surgery
• Anyone taking iron supplements for diagnosed iron deficiency, since curcumin can bind non-heme iron and reduce its absorption if taken at the same time

This article does not set a specific milligram threshold, injection dose, or timing schedule as a recommendation. AOD-9604 dosing is set by the prescribing clinician and compounding pharmacy protocol, and curcumin dosing decisions, especially above standard supplement-label amounts, should be made with that same clinician rather than from general guidance.

What remains genuinely unverified

AOD-9604 never completed Phase III development, so there is no FDA-reviewed labeling, no formal drug-interaction study program, and no large post-marketing safety database for this peptide at all, let alone in combination with a specific botanical supplement. Everything above is built from the separate, better-established pharmacology of curcumin and the more limited, earlier-phase pharmacology of AOD-9604, plus straightforward mechanistic reasoning about where their activities overlap. That is a legitimate way to reason about a novel combination, but it is not the same as clinical trial evidence, and readers should not treat the dose thresholds and risk categories above as clinically validated numbers. If a compounding pharmacy, prescriber, or professional body such as the American Association of Clinical Endocrinologists has published more specific guidance on monitoring supplement use alongside compounded peptide therapy since this article was written, that guidance should take precedence.

When to seek urgent care rather than wait for a routine follow-up

Unexplained or spreading bruising, blood in urine or stool, unusually heavy or prolonged bleeding from a minor cut, or bleeding gums that do not resolve should prompt a call to the prescribing clinician the same day, and emergency evaluation if bleeding is heavy or will not stop. These are not expected effects of either agent at typical supplement doses, and their appearance should not be assumed to be a benign side effect of the combination.